Chimerix, Inc.
Chimerix, Inc. has developed a heparin-derived blood cancer drug could reduce inflammation and hypercoagulation in COVID-19 patients with acute lung injury (ALI).
Rankings by 
National Ranking
443rd
in United StatesRegional Ranking
502nd
in North America and CaribbeanGlobal Ranking
1216th
worldwide